LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Structure and antigenicity of divergent Henipavirus fusion glycoproteins.

Isaacs, Ariel / Low, Yu Shang / Macauslane, Kyle L / Seitanidou, Joy / Pegg, Cassandra L / Cheung, Stacey T M / Liang, Benjamin / Scott, Connor A P / Landsberg, Michael J / Schulz, Benjamin L / Chappell, Keith J / Modhiran, Naphak / Watterson, Daniel

Nature communications

2023 Volume 14, Issue 1, Page(s) 3577

Abstract: In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China. This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah ( ... ...

Abstract	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China. This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses. The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health. In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively. We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera. Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV. These findings explain the distinct antigenic profile of LayV and MojV F, despite the extent to which they are otherwise structurally similar to NiV. Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
MeSH term(s)	Humans ; Henipavirus ; Glycoproteins/metabolism ; Viral Proteins/metabolism ; Henipavirus Infections ; Nipah Virus/metabolism
Chemical Substances	Glycoproteins ; Viral Proteins
Language	English
Publishing date	2023-06-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-39278-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates

Isaacs, Ariel / Cheung, Stacey T. M. / Thakur, Nazia / Jaberolansar, Noushin / Young, Andrew / Modhiran, Naphak / Bailey, Dalan / Graham, Simon P. / Young, Paul R. / Chappell, Keith J. / Watterson, Daniel

Viruses. 2021 Sept. 28, v. 13, no. 10

2021

Abstract: Nipah virus (NiV) and respiratory syncytial virus (RSV) possess two surface glycoproteins involved in cellular attachment and membrane fusion, both of which are potential targets for vaccines. The majority of vaccine development is focused on the ... ...

Abstract	Nipah virus (NiV) and respiratory syncytial virus (RSV) possess two surface glycoproteins involved in cellular attachment and membrane fusion, both of which are potential targets for vaccines. The majority of vaccine development is focused on the attachment (G) protein of NiV, which is the immunodominant target. In contrast, the fusion (F) protein of RSV is the main target in vaccine development. Despite this, neutralising epitopes have been described in NiV F and RSV G, making them alternate targets for vaccine design. Through rational design, we have developed a vaccine strategy applicable to phylogenetically divergent NiV and RSV that comprises both the F and G proteins (FxG). In a mouse immunization model, we found that NiV FxG elicited an improved immune response capable of neutralising pseudotyped NiV and a NiV mutant that is able to escape neutralisation by two known F-specific antibodies. RSV FxG elicited an immune response against both F and G and was able to neutralise RSV; however, this was inferior to the immune response of F alone. Despite this, RSV FxG elicited a response against a known protective epitope within G that is conserved across RSV A and B subgroups, which may provide additional protection in vivo. We conclude that inclusion of F and G antigens within a single design provides a streamlined subunit vaccine strategy against both emerging and established pathogens, with the potential for broader protection against NiV.
Keywords	Nipah henipavirus ; Respiratory syncytial virus ; epitopes ; glycoproteins ; immune response ; immunization ; membrane fusion ; mice ; models ; mutants ; neutralization ; phylogeny ; subunit vaccines ; vaccine development
Language	English
Dates of publication	2021-0928
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2516098-9
ISSN	1999-4915
ISSN	1999-4915
DOI	10.3390/v13101942
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article: Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines.

Isaacs, Ariel / Li, Zheyi / Cheung, Stacey T M / Wijesundara, Danushka K / McMillan, Christopher L D / Modhiran, Naphak / Young, Paul R / Ranasinghe, Charani / Watterson, Daniel / Chappell, Keith J

Vaccines

2021 Volume 9, Issue 2

Abstract: Subunit vaccines exhibit favorable safety and immunogenicity profiles and can be designed to mimic native antigen structures. However, pairing with an appropriate adjuvant is imperative in order to elicit effective humoral and cellular immune responses. ... ...

Abstract	Subunit vaccines exhibit favorable safety and immunogenicity profiles and can be designed to mimic native antigen structures. However, pairing with an appropriate adjuvant is imperative in order to elicit effective humoral and cellular immune responses. In this study, we aimed to determine an optimal adjuvant pairing with the prefusion form of influenza haemagglutinin (HA) or respiratory syncytial virus (RSV) fusion (F) subunit vaccines in BALB/c mice in order to inform future subunit vaccine adjuvant selection. We tested a panel of adjuvants, including aluminum hydroxide (alhydrogel), QS21, Addavax, Addavax with QS21 (AdQS21), and Army Liposome Formulation 55 with monophosphoryl lipid A and QS21 (ALF55). We found that all adjuvants elicited robust humoral responses in comparison to placebo, with the induction of potent neutralizing antibodies observed in all adjuvanted groups against influenza and in AdQS21, alhydrogel, and ALF55 against RSV. Upon HA vaccination, we observed that none of the adjuvants were able to significantly increase the frequency of CD4
Language	English
Publishing date	2021-01-20
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines9020071
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates.

Isaacs, Ariel / Cheung, Stacey T M / Thakur, Nazia / Jaberolansar, Noushin / Young, Andrew / Modhiran, Naphak / Bailey, Dalan / Graham, Simon P / Young, Paul R / Chappell, Keith J / Watterson, Daniel

Viruses

2021 Volume 13, Issue 10

Abstract	Nipah virus (NiV) and respiratory syncytial virus (RSV) possess two surface glycoproteins involved in cellular attachment and membrane fusion, both of which are potential targets for vaccines. The majority of vaccine development is focused on the attachment (G) protein of NiV, which is the immunodominant target. In contrast, the fusion (F) protein of RSV is the main target in vaccine development. Despite this, neutralising epitopes have been described in NiV F and RSV G, making them alternate targets for vaccine design. Through rational design, we have developed a vaccine strategy applicable to phylogenetically divergent NiV and RSV that comprises both the F and G proteins (FxG). In a mouse immunization model, we found that NiV FxG elicited an improved immune response capable of neutralising pseudotyped NiV and a NiV mutant that is able to escape neutralisation by two known F-specific antibodies. RSV FxG elicited an immune response against both F and G and was able to neutralise RSV; however, this was inferior to the immune response of F alone. Despite this, RSV FxG elicited a response against a known protective epitope within G that is conserved across RSV A and B subgroups, which may provide additional protection in vivo. We conclude that inclusion of F and G antigens within a single design provides a streamlined subunit vaccine strategy against both emerging and established pathogens, with the potential for broader protection against NiV.
MeSH term(s)	Animals ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Female ; Henipavirus Infections/prevention & control ; Humans ; Mice ; Mice, Inbred BALB C ; Nipah Virus/immunology ; Respiratory Syncytial Virus Infections/prevention & control ; Respiratory Syncytial Virus Vaccines/administration & dosage ; Respiratory Syncytial Virus Vaccines/immunology ; Respiratory Syncytial Virus, Human/immunology ; Vaccine Development/methods ; Vaccines, Subunit/administration & dosage ; Vaccines, Subunit/immunology ; Viral Envelope Proteins/administration & dosage ; Viral Envelope Proteins/genetics ; Viral Envelope Proteins/immunology ; Viral Fusion Proteins/immunology
Chemical Substances	Antibodies, Viral ; Respiratory Syncytial Virus Vaccines ; Vaccines, Subunit ; Viral Envelope Proteins ; Viral Fusion Proteins
Language	English
Publishing date	2021-09-28
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v13101942
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2.

Amarilla, Alberto A / Modhiran, Naphak / Setoh, Yin Xiang / Peng, Nias Y G / Sng, Julian D J / Liang, Benjamin / McMillan, Christopher L D / Freney, Morgan E / Cheung, Stacey T M / Chappell, Keith J / Khromykh, Alexander A / Young, Paul R / Watterson, Daniel

Frontiers in microbiology

2021 Volume 12, Page(s) 625136

Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as the causative agent of coronavirus disease 2019 and is capable of human-to-human transmission and rapid global spread. The rapid emergence and global spread of SARS-CoV-2 ...

Abstract	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as the causative agent of coronavirus disease 2019 and is capable of human-to-human transmission and rapid global spread. The rapid emergence and global spread of SARS-CoV-2 has encouraged the establishment of a rapid, sensitive, and reliable viral detection and quantification methodology. Here, we present an alternative assay, termed immuno-plaque assay (iPA), which utilizes a combination of plaque assay and immunofluorescence techniques. We have extensively optimized the conditions for SARS-CoV-2 infection and demonstrated the great flexibility of iPA detection using several antibodies and dual-probing with two distinct epitope-specific antibodies. In addition, we showed that iPA could be utilized for ultra-high-throughput viral titration and neutralization assay within 24 h and is amenable to a 384-well format. These advantages will significantly accelerate SARS-CoV-2 research outcomes during this pandemic period.
Language	English
Publishing date	2021-02-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587354-4
ISSN	1664-302X
ISSN	1664-302X
DOI	10.3389/fmicb.2021.625136
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.

McMillan, Christopher L D / Cheung, Stacey T M / Modhiran, Naphak / Barnes, James / Amarilla, Alberto A / Bielefeldt-Ohmann, Helle / Lee, Leo Yi Yang / Guilfoyle, Kate / van Amerongen, Geert / Stittelaar, Koert / Jakob, Virginie / Lebas, Celia / Reading, Patrick / Short, Kirsty R / Young, Paul R / Watterson, Daniel / Chappell, Keith J

NPJ vaccines

2022 Volume 7, Issue 1, Page(s) 3

Language	English
Publishing date	2022-01-05
Publishing country	England
Document type	Published Erratum
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-021-00428-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A platform technology for generating subunit vaccines against diverse viral pathogens.

Frontiers in immunology

2022 Volume 13, Page(s) 963023

Abstract: The COVID-19 pandemic response has shown how vaccine platform technologies can be used to rapidly and effectively counteract a novel emerging infectious disease. The speed of development for mRNA and vector-based vaccines outpaced those of subunit ... ...

Abstract	The COVID-19 pandemic response has shown how vaccine platform technologies can be used to rapidly and effectively counteract a novel emerging infectious disease. The speed of development for mRNA and vector-based vaccines outpaced those of subunit vaccines, however, subunit vaccines can offer advantages in terms of safety and stability. Here we describe a subunit vaccine platform technology, the molecular clamp, in application to four viruses from divergent taxonomic families: Middle Eastern respiratory syndrome coronavirus (MERS-CoV), Ebola virus (EBOV), Lassa virus (LASV) and Nipah virus (NiV). The clamp streamlines subunit antigen production by both stabilising the immunologically important prefusion epitopes of trimeric viral fusion proteins while enabling purification without target-specific reagents by acting as an affinity tag. Conformations for each viral antigen were confirmed by monoclonal antibody binding, size exclusion chromatography and electron microscopy. Notably, all four antigens tested remained stable over four weeks of incubation at 40°C. Of the four vaccines tested, a neutralising immune response was stimulated by clamp stabilised MERS-CoV spike, EBOV glycoprotein and NiV fusion protein. Only the clamp stabilised LASV glycoprotein precursor failed to elicit virus neutralising antibodies. MERS-CoV and EBOV vaccine candidates were both tested in animal models and found to provide protection against viral challenge.
MeSH term(s)	Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 ; Humans ; Middle East Respiratory Syndrome Coronavirus ; Pandemics ; Spike Glycoprotein, Coronavirus ; Technology ; Vaccines, Subunit ; Viral Vaccines
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; Vaccines, Subunit ; Viral Vaccines ; spike protein, SARS-CoV-2
Language	English
Publishing date	2022-08-18
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.963023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern.

McMillan, Christopher L D / Azuar, Armira / Choo, Jovin J Y / Modhiran, Naphak / Amarilla, Alberto A / Isaacs, Ariel / Honeyman, Kate E / Cheung, Stacey T M / Liang, Benjamin / Wurm, Maria J / Pino, Paco / Kint, Joeri / Fernando, Germain J P / Landsberg, Michael J / Khromykh, Alexander A / Hobson-Peters, Jody / Watterson, Daniel / Young, Paul R / Muller, David A

Vaccines

2022 Volume 10, Issue 4

Abstract: The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to disrupt essential health services in 90 percent of countries today. The spike (S) protein found on the surface of the causative agent, the SARS-CoV-2 virus, has been the prime target ... ...

Abstract	The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to disrupt essential health services in 90 percent of countries today. The spike (S) protein found on the surface of the causative agent, the SARS-CoV-2 virus, has been the prime target for current vaccine research since antibodies directed against the S protein were found to neutralize the virus. However, as new variants emerge, mutations within the spike protein have given rise to potential immune evasion of the response generated by the current generation of SARS-CoV-2 vaccines. In this study, a modified, HexaPro S protein subunit vaccine, delivered using a needle-free high-density microarray patch (HD-MAP), was investigated for its immunogenicity and virus-neutralizing abilities. Mice given two doses of the vaccine candidate generated potent antibody responses capable of neutralizing the parental SARS-CoV-2 virus as well as the variants of concern, Alpha and Delta. These results demonstrate that this alternative vaccination strategy has the potential to mitigate the effect of emerging viral variants.
Language	English
Publishing date	2022-04-08
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines10040578
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Efficient Delivery of Dengue Virus Subunit Vaccines to the Skin by Microprojection Arrays.

Muller, David A / Depelsenaire, Alexandra C I / Shannon, Ashleigh E / Watterson, Daniel / Corrie, Simon R / Owens, Nick S / Agyei-Yeboah, Christiana / Cheung, Stacey T M / Zhang, Jin / Fernando, Germain J P / Kendall, Mark A F / Young, Paul R

Vaccines

2019 Volume 7, Issue 4

Abstract: Dengue virus is the most important arbovirus impacting global human health, with an estimated 390 million infections annually, and over half the world's population at risk of infection. While significant efforts have been made to develop effective ... ...

Abstract	Dengue virus is the most important arbovirus impacting global human health, with an estimated 390 million infections annually, and over half the world's population at risk of infection. While significant efforts have been made to develop effective vaccines to mitigate this threat, the task has proven extremely challenging, with new approaches continually being sought. The majority of protective, neutralizing antibodies induced during infection are targeted by the envelope (E) protein, making it an ideal candidate for a subunit vaccine approach. Using truncated, recombinant, secreted E proteins (sE) of all 4 dengue virus serotypes, we have assessed their immunogenicity and protective efficacy in mice, with or without Quil-A as an adjuvant, and delivered via micropatch array (MPA) to the skin in comparison with more traditional routes of immunization. The micropatch contains an ultra-high density array (21,000/cm
Language	English
Publishing date	2019-11-20
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines7040189
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.

NPJ vaccines

2021 Volume 6, Issue 1, Page(s) 135

Abstract: Influenza viruses cause a significant number of infections and deaths annually. In addition to seasonal infections, the risk of an influenza virus pandemic emerging is extremely high owing to the large reservoir of diverse influenza viruses found in ... ...

Abstract	Influenza viruses cause a significant number of infections and deaths annually. In addition to seasonal infections, the risk of an influenza virus pandemic emerging is extremely high owing to the large reservoir of diverse influenza viruses found in animals and the co-circulation of many influenza subtypes which can reassort into novel strains. Development of a universal influenza vaccine has proven extremely challenging. In the absence of such a vaccine, rapid response technologies provide the best potential to counter a novel influenza outbreak. Here, we demonstrate that a modular trimerization domain known as the molecular clamp allows the efficient production and purification of conformationally stabilised prefusion hemagglutinin (HA) from a diverse range of influenza A subtypes. These clamp-stabilised HA proteins provided robust protection from homologous virus challenge in mouse and ferret models and some cross protection against heterologous virus challenge. This work provides a proof-of-concept for clamp-stabilised HA vaccines as a tool for rapid response vaccine development against future influenza A virus pandemics.
Language	English
Publishing date	2021-11-08
Publishing country	England
Document type	Journal Article
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-021-00395-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED